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Biased agonism describes the ability of ligands to stabilize different conformations of a GPCR
linked to distinct functional outcomes and offers the prospect of designing pathway-speciﬁc
drugs that avoid on-target side effects. This mechanism is usually inferred from pharmaco-
logical data with the assumption that the confounding inﬂuences of observational (that is,
assay dependent) and system (that is, cell background dependent) bias are excluded by
experimental design and analysis. Here we reveal that ‘kinetic context’, as determined by
ligand-binding kinetics and the temporal pattern of receptor-signalling processes, can have a
profound inﬂuence on the apparent bias of a series of agonists for the dopamine D2 receptor
and can even lead to reversals in the direction of bias. We propose that kinetic context must
be acknowledged in the design and interpretation of studies of biased agonism.
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I
n recent years, the phenomenon of ‘biased agonism’
has evolved from a theoretical concept of drug–receptor
interaction to an established paradigm that is having a major
impact on drug discovery1,2. Biased agonism describes the ability
of different ligands to stabilize distinct conformations of a given
receptor such that only a subset of the possible signalling
repertoires mediated by the receptor are engaged to the relative
exclusion of others3. To date, biased agonism has been intensively
investigated in studies of G protein-coupled receptors (GPCRs),
the largest class of drug targets4, but it is likely to be a more
universal paradigm.
The promise of biased agonism is the ability to design ligands
that selectively engage therapeutically relevant signalling path-
ways, while sparing those that contribute to undesirable side
effects mediated by the same target. Indeed, biased ligands are
currently being pursued in clinical trials for a number of
applications5. Biased agonism may also explain why some drugs
from a common target class (for example, b-blockers) display
clinical efﬁcacy (for example, in heart failure), whereas others fail,
despite showing similar degrees of efﬁcacy in particular
preclinical indices of biological activity6–8. As the mechanistic
link between cellular measures of drug–receptor efﬁcacy and their
role in vivo remains ill deﬁned for many diseases, preclinical
studies often focus on pathways that are ultimately not associated
with the pathophysiology under investigation; failure to
appreciate and capture biased agonism in such circumstances
can lead to costly translational failures.
Recent studies have focused on various means for detecting
biased agonists and quantifying their behaviour to inform
structure–activity studies. For predictive and translational
purposes, a critical aspect of any quantitative analysis of bias is
the need to remove the inﬂuence of the cellular background (that
is, ‘system bias’ as reﬂected by effector–transducer complement,
stoichiometry, coupling efﬁciency and so on) and the assay
conditions (that is, ‘observational bias’) when comparing the
activity of a group of agonists between pathways in the same cell
type2,3,9. In this regard, a number of analytical methods have
been developed that build on the seminal operational model of
agonism proposed by Black and Leff9–12. The key drug–receptor
parameters in these models are the equilibrium dissociation
constant of the agonist for the receptor (KA) and an operational
measure of signalling efﬁcacy (t) that subsumes both receptor
density and coupling efﬁciency to a given pathway. The t/KA
ratio (‘transducer ratio’) can thus be used as an index of the
intrinsic relative activity of an agonist at a given pathway and
represents a starting point for quantiﬁcation of biased agonism.
Normalizing this value for a test agonist relative to a reference
agonist has been proposed to nullify the impact of system and
observational bias10.
An example of a prototypical GPCR at which biased agonism
has been extensively studied is the dopamine D2 receptor (D2R),
an important therapeutic target for the treatment of neuro-
psychiatric disorders, including schizophrenia13. Prior evidence
suggests that biased agonism at the D2R may be important for the
antipsychotic activity of the partial agonist, aripiprazole14–17.
However, a clear relationship between biased agonism at the D2R
and antipsychotic efﬁcacy remains elusive, not least due to
discrepancies in the literature. For example, a recent study
demonstrated that potent b-arrestin-biased D2R agonists were
effective in preclinical animal models of psychosis15; however,
earlier studies suggested that antagonism of b-arrestin
recruitment is required for antipsychotic efﬁcacy16. Our own
work revealed that aripiprazole is biased towards the inhibition
of cyclic AMP production as compared with ERK1/2
phosphorylation; however, this ﬁnding was inconsistent with an
earlier study17,18.
It is likely to be that some of the discrepancies between studies
of bias for the same ligand–receptor pairings are due to a failure
to appreciate the impact of system or observational bias. In
particular, the timescales of measurement of receptor signalling
can vary greatly depending on the pathways under investigation
and the type of readout19; however, all receptor models for
quantifying bias assume an equilibrium. Thus, the spatiotemporal
pattern of agonist action may be quite different depending on
agonist-binding kinetics or if agonists differentially engage
dynamic signalling and regulatory processes. Indeed, the
inﬂuence of kinetics on measured drug response has long been
acknowledged in the study of enzymes and receptors20. However,
such spatiotemporal patterns of drug action may have a profound
inﬂuence on the detection and interpretation of biased agonism,
in particular when comparing transient responses with those
measured over longer time scales. This also raises the possibility
that the observed bias of a ligand may depend on the timescale(s)
over which its effect is measured at different pathways.
This study is the ﬁrst to systematically explore the inﬂuence of
‘kinetic context’, as reﬂected by system and observational bias, on
selected D2R agonists at multiple signalling pathways. We
demonstrate that the major contributor to context-dependent
changes in the observed bias proﬁle of D2R ligands is the
interplay between differential ligand-binding kinetics and the
kinetics associated with different cell signalling processes, in some
instances leading to complete reversals of agonist bias over time.
These ﬁndings have major implications for the identiﬁcation,
quantiﬁcation and interpretation of biased agonism at GPCRs.
Results
Detection of biased agonism at the D2R. The D2R partial
agonists selected for this study were (S)-(-)-3-(3-hydroxyphenyl)-
N-propylpiperidine (S-3PPP), bifeprunox, cariprazine, aripipra-
zole and pardoprunox (Supplementary Fig. 1). Aripiprazole and
cariprazine are D2R partial agonists approved as antipsychotics,
whereas S-3PPP and bifeprunox were withdrawn from clinical
trials due to limited antipsychotic efﬁcacy21–23. Pardoprunox has
undergone clinical trials for the treatment of Parkinson’s disease.
The high efﬁcacy agonist ropinirole (used clinically to treat
Parkinson’s disease) and the endogenous agonist dopamine were
used as reference ligands24. The action of these agonists was
assessed at the following signalling endpoints using Flp-In-CHO
cells stably expressing the long isoform of the D2R (Flp-In-CHO-
D2LR), ERK1/2 phosphorylation (pERK1/2; Fig. 1a and
Supplementary Data 1), inhibition of forskolin-induced cAMP
production (Fig. 1b) and b-arrestin-2 recruitment (Fig. 1c). In
addition, we measured activation of both Gai1 and GaoB G
proteins using bioluminescence resonance energy transfer
(BRET)-based biosensors, as previous studies have suggested
that dopamine receptor ligands differentially activate these G
proteins (Fig. 1d,e)25,26. The xCELLigence system was used to
evaluate the effect of the agonists on cellular impedance (CI) as a
more ‘global’ readout that can capture multiple convergent
signalling events triggered on receptor activation (Fig. 1f)27. The
most transient signalling response was pERK1/2 with maximal
stimulation of pERK1/2 by 10 mM dopamine occurring at 5min
before a rapid return to near-basal levels after 15min (Fig. 1a).
Therefore, we ﬁrst chose a 5-min time window for all assays, to
compare bias at a single time point.
Using concentration–response data obtained at 5min for all
assays (Fig. 2a–f), to determine whether the different D2R
agonists display biased agonism, we used the operational model
to derive a transduction coefﬁcient (t/KA) for each agonist at each
pathway (Supplementary Table 1)10. The log(t/KA) values were
normalized to that of dopamine at each pathway (Dlog(t/KA);
Supplementary Table 2) and compared across different signalling
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pathways to give a DDlog(t/KA) or LogBias value (Supplementary
Table 3)10. The Bias (antilog) values were graphically represented
in a web, to illustrate a speciﬁc bias ‘ﬁngerprint’ for each
individual ligand (Fig. 3a). The agonists pardoprunox and
ropinirole had a similar pattern of bias to that of dopamine.
S-3PPP displayed moderate (less than tenfold) bias between the
activation of Gai1 and all other assays apart from the activation
of GaoB where there was no signiﬁcant bias. Bifeprunox,
aripiprazole and cariprazine had a bias ﬁngerprint distinct from
that of dopamine and the other agonists predominantly due to
lower efﬁcacy in ERK1/2 phosphorylation as compared with
other signalling assays. In addition, bifeprunox and aripiprazole
were signiﬁcantly (one-way analysis of variance with Tukey’s post
test, Po0.05) more biased as compared with dopamine towards
the activation of Gai1 proteins compared with CI and inhibition
of cAMP production. Bifeprunox was the only compound to
display signiﬁcant bias between the activation of Gai1 versus
GaoB G proteins. None of the agonists displayed bias between
inhibition of cAMP production and the CI response. As S-3PPP
and cariprazine did not give a complete concentration–response
curve for b-arrestin-2 recruitment, we could not quantify
their action at this pathway. Therefore, we have not included
b-arrestin-2 recruitment in the web of bias but rather displayed
the bias factors of the agonists between b-arrestin-2 recruitment
and other signalling pathways in Supplementary Fig. 2 and
Supplementary Table 4. Only bifeprunox displayed bias towards
the activation of both Gai1 and GaoB G proteins versus b-
arrestin-2 recruitment and bias towards b-arrestin-2 recruitment
versus ERK1/2 phosphorylation.
Our comparisons of the action of different ligands across
multiple pathways are intrinsically multi-dimensional. We made
use of principal component analysis (PCA) to distil this multi-
dimensional data set into principal components, to allow us to
cluster ligands into distinct bias groupings relative to dopamine
(Fig. 3b)28. In this analysis, PC1 represents 90% of the variance
and clearly demonstrates that the ligands can be subdivided into
two groups based on their bias proﬁle, with ropinirole, dopamine,
S-3PPP and pardoprunox in one group and aripiprazole,
bifeprunox and cariprazine in another (Fig. 3b). PC2 represents
an additional 7% of the variance and further separates S-3PPP
and cariprazine from their respective groups. Therefore, our
quantitative approach to determining bias allowed the statistical
clustering of ligands into distinct bias groupings that encompass
their action across multiple pathways.
Biased agonists display slower dissociation rates. Most
measurements of receptor function are made under non-
equilibrium conditions where the receptor occupancy of a ligand
may differ depending on the time at which the measurement is
made. This in turn may affect agonist potency29 and, if there are
marked differences in binding kinetics within a subset of ligands,
this could be interpreted as biased agonism. However, to our
knowledge, the impact of binding kinetics on biased agonism has
not yet been examined experimentally.
To determine the kinetic binding parameters of our selected
D2R ligands, we conducted competition association binding
experiments using membranes of Flp-In-CHO-D2LR and the
antagonist [3H]spiperone30–32 in the presence of 100 mM
Gpp(NH)p, to ensure that we were measuring ligand binding
only to the G protein-uncoupled receptor state33. Although
we were able to determine values of association (kon) and
dissociation (koff) rate constants for the ligands that displayed a
distinct bias proﬁle at the 5-min time point (cariprazine,
bifeprunox and aripiprazole), we could not do so for dopamine,
ropinirole, pardoprunox and S-3PPP (Supplementary Table 5),
most probably because the dissociation rate of [3H]spiperone
(0.026min 1) is slow relative to that of these four agonists.
We extended these studies with a Tag-lite receptor binding
assay using a D2R construct with an amino-terminal SNAP tag
and the ﬂuorescently labelled agonist (±)-40-amino-2-(N-phe-
nethyl-N-propyl)-amino-5-hydroxytetralin (PPHT). This ligand
displays a faster rate of dissociation (0.45min 1) than that of
[3H]spiperone and enabled us to obtain accurate values for all
ligands (Fig. 4 and Supplementary Table 6). These assays were
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Figure 1 | Kinetic traces of the cellular response on activation of the D2LR with various agonists. The effect of dopamine (10 mM), ropinirole (10mM),
aripiprazole (10 mM), cariprazine (1 mM), bifeprunox (10mM), pardoprunox (10 mM) and S-3PPP (10 mM) on ERK1/2 phosphorylation (a), the inhibition of
forskolin-induced cAMP production (b), b-arrestin-2 recruitment (c), activation of GaoB (d) and Gai1 (e) G proteins, and CI (f) is shown for a period of
30–90min. The data points are expressed as mean±s.e.m. from three (cAMP, GaoB, Gai1 and b-arrestin-2 recruitment) or four (ERK1/2 phosphorylation
and CI) experiments performed in duplicate. Duplicates were averaged before calculating s.e.m. The raw data are included as Supplementary Data 1.
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performed using cell membranes in the presence of 100 mM
Gpp(NH)p, to ensure we were measuring binding to the same G
protein-uncoupled receptor state as measured using [3H]spiper-
one as a probe. As expected, dopamine, ropinirole, pardoprunox
and S-3PPP displayed faster dissociation kinetics than aripipra-
zole, bifeprunox or cariprazine (Fig. 4b). The association rate of a
ligand is often thought to be diffusion limited34. However, our
data reveal signiﬁcant variability in the association rate of our
selected ligands, with differences of over three orders of
magnitude (Fig. 4a and Supplementary Table 6). Therefore, the
different afﬁnity of these compounds is driven by both differences
in dissociation and association rates35. Of note, values of t1/2
determined for cariprazine, aripiprazole and bifeprunox matched
those determined using [3H]spiperone as the tracer ligand (Fig. 4c
and Supplementary Tables 5 and 6), indicating that the addition
of the SNAP tag did not affect the binding of these ligands.
Furthermore, values of afﬁnity calculated using these kinetic
parameters correlate with values obtained in competition binding
experiments with [3H]spiperone (Fig. 4d). Using these kinetic
parameters, we performed a simulation to estimate the receptor
occupancy of a KD concentration of each agonist over time
(Fig. 4e). This revealed that dopamine, ropinirole, pardoprunox
and S-3PPP reached maximal receptor occupancy within 1min,
whereas maximal occupancy for cariprazine and aripiprazole was
reached after B10min, and that bifeprunox would not reach
maximal occupancy even after 90min.
Biased agonism can change profoundly with time. It has been
previously demonstrated that different signalling pathways
have distinct kinetic proﬁles, for example, the fast or sustained
pERK1/2 signal mediated by the b2 adrenergic or angiotensin II
receptors relating to a G protein versus b arrestin signalling
pathway, respectively36,37. We hypothesized that the different
binding kinetics and the temporal pattern of different signalling
processes would together manifest in a change in the bias
observed for a ligand over time. To address this hypothesis,
we took advantage of both the BRET-based biosensors
and xCELLigence technology that allow kinetic resolution
of intracellular signalling events. We measured the effect of
increasing concentrations of agonists on the inhibition of cAMP
production, the activation of GaoB G proteins and CI at various
time points ranging from 2 to 90min (Fig. 5 and Supplementary
Fig. 3). Importantly, all agonists maintained a robust signal up to
90min at these signalling endpoints (Fig. 1).
Ligands with slower dissociation kinetics (aripiprazole and
bifeprunox) demonstrated an increase in potency over time in all
three assays, which can be attributed to an increase in receptor
occupancy over time. Indeed, the order of the three ligands in
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Figure 2 | Characterization of D2R agonists at a range of signalling endpoints after 5min of agonist stimulation. The ability of increasing concentrations
of D2R agonists to induce ERK1/2 phosphorylation (a), inhibit 10 mM forskolin-induced cAMP production (b), induce b-arrestin2 recruitment (c),
activate GaoB (d) and Gai1 (e) G proteins and induce changes in CI (f) in Flp-In-CHO cells expressing the D2LR. The data were normalized to the maximal
response induced by dopamine and ﬁtted using an operational model of agonism (equation (2)). The values are expressed as mean±s.e.m. of three
experiments performed in duplicate; duplicates were averaged before calculating s.e.m.
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terms of magnitude of increase in potency over time was the
same as the order of their decreasing rate of dissociation
(Supplementary Tables 6 and 7). In contrast, we observed a
decrease in potency over time for ligands with fast dissociation
kinetics (dopamine, ropinirole, S-3PPP and pardoprunox) in both
the cAMP and xCELLigence assay, but either no change in
potency (dopamine and ropinirole) or a modest increase in
potency (pardoprunox: sixfold and S-3PPP: twofold) in the GaoB
activation assay (Supplementary Table 7). This effect cannot be
attributed solely to different binding kinetics and suggests that
different signalling endpoints are subject to desensitization or
regulatory processes that differentially affect the potency and/or
efﬁcacy of different ligands over time.
We used these data to quantify bias at different time points
(using ropinirole as the reference agonist), to determine whether
these changes in potency over time led to changes in calculated
values of bias (Fig. 6 and Supplementary Fig. 4). Although the
cognate agonist, dopamine, is released and acts transiently in vivo,
many synthetic agonists, such as ropinirole, are administered
chronically to patients and will therefore produce prolonged D2R
activation. Furthermore, we could not exclude the possibility that
dopamine may be oxidized after long incubation times (ascorbic
acid could not be used in our BRET assays due to the interference
with luciferase activity). Therefore, for these experiments, we
chose to use ropinirole rather than dopamine as the reference
agonist. Notably, in the case of bifeprunox and aripiprazole,
the direction of bias between pathways was reversed over time
(Fig. 6). Bifeprunox displayed signiﬁcant bias towards the
activation of GaoB G proteins versus inhibition of cAMP
production at earlier time points, whereas at later time points it
displayed signiﬁcant bias towards inhibition of cAMP production.
Similarly, bifeprunox and aripiprazole were signiﬁcantly biased
towards the activation of GaoB G proteins versus the CI response
at earlier time points, whereas this was reversed at later time
points, with a striking 200-fold change in bias for aripiprazole
between 2 and 90min. This change in observed bias must be
manifested both by the increase in potency over time observed for
the ligands with slower dissociation kinetics (bifeprunox,
aripiprazole and cariprazine) and different patterns of changing
potency (decreased in cAMP and CI, no change in GaoB G
protein activation) of the reference ligand ropinirole and the
other ligands with faster kinetics. These effects also confer
changes in the overall pattern of biased agonism between the
three pathways, as illustrated by webs of bias generated from
measurements taken at 2, 10 and 90-min time points (Fig. 6j). At
2min, there is a clear distinction between cariprazine, aripipra-
zole and bifeprunox in comparison with the other ligands driven
by their bias towards GaoB G protein activation in comparison
with CI and cAMP. At 10min, none of the ligands are
signiﬁcantly biased relative to ropinirole. At 90min, bifeprunox
and aripiprazole again show a distinct observed bias proﬁle to
ropinirole but with a reversal in direction away from GaoB G
protein activation. Thus, although the direction of observed bias
has changed, these ligands retain a bias proﬁle different from that
of ropinirole. In contrast, cariprazine displays no bias at 90min.
Interestingly, at this time point, dopamine displays signiﬁcant
bias compared with ropinirole and has a similar bias proﬁle to
cariprazine, bifeprunox and aripiprazole, illustrating that even the
endogenous agonist has a natural signalling pleiotropy that can
change over time.
We hypothesized that both differential ligand binding and
signalling kinetics may confer apparent biased agonism if
measurements of agonist action at a single pathway are compared
at different time points. To explore this, we compared the effect of
the agonists at a single pathway (the inhibition of forskolin-
stimulated cAMP), whereby agonist effect was measured
at a single 30-min time point using an Alphascreen assay
(Supplementary Fig. 5), or determined at multiple time points
using the BRET-based cAMP biosensor. In agreement with their
slow dissociation rate, cariprazine, bifeprunox and aripiprazole all
displayed signiﬁcant ‘bias’ towards the measurements of agonist
action using the Alphascreen assay measured at 30min compared
with measurements using the BRET biosensor between 2 and
10min. When measurements were made at a 30-min time point
for both assays, all the ligands displayed less than threefold
difference in bias compared with ropinirole. Although both
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cariprazine and aripiprazole did not display signiﬁcant bias after
30min, bifeprunox became signiﬁcantly ‘biased’ towards the
BRET-based cAMP assay, because the potency of bifeprunox was
underestimated at a 30-min time point, in agreement with its
much slower rate of receptor occupancy (Fig. 4e).
The time point chosen at which to measure agonist action at a
certain pathway often reﬂects an optimal signal window for a
reference agonist. Indeed, the agonist response may be transient
in some signalling pathways, as is the case for ERK1/2
phosphorylation where a peak response is observed between 5
and 10min (Fig. 1). In this case, although the maximal response
gained from a ligand with fast dissociation rates such as
dopamine will represent high receptor occupancy, this will not
be true for slower ligands such as bifeprunox. We quantiﬁed
biased agonism between ERK1/2 phosphorylation after 5min of
agonist stimulation and the inhibition of forskolin-induced cAMP
production after different incubation times (Supplementary
Fig. 6). As expected, the ligands with slower dissociation kinetics,
aripiprazole, cariprazine and bifeprunox, became more biased
towards cAMP inhibition, because they displayed a time-
dependent increase in potency for inhibition of cAMP production
as opposed to the loss of potency over time observed for ligands
such as ropinirole.
Discrepancies in the biased action of aripiprazole. We
hypothesized that observational bias caused by differences in
experimental conditions may explain prior discrepancies in the
action of aripiprazole between two studies, speciﬁcally between a
recent publication by Szabo et al.17 and that of Tschammer
et al.18. The former found that aripiprazole was biased towards
inhibition of cAMP production versus ERK1/2 phosphorylation
as compared with dopamine but the latter did not. Two notable
differences in experimental conditions between the studies are the
temperature and time at which the cAMP assay was conducted
and measured (37 C and 30min compared with 25 C and
15min, respectively). In contrast, the conditions of the pERK1/2
assay were the same in both studies (5min agonist stimulation at
37 C)17,18. To test this hypothesis, we measured inhibition of
forskolin-stimulated cAMP at both 25 and 37 C. Ligands with
similarly fast dissociation kinetics as dopamine (ropinirole,
pardoprunox and S-3PPP) were affected in a similar manner
by the change in temperature, which resulted in no change
in transduction coefﬁcient (Dlog(t/KA)) values normalized to
dopamine (Fig. 7a–c). However, ligands that have slower binding
kinetics (aripiprazole, cariprazine and bifeprunox) compared with
dopamine, displayed different Dlog(t/KA) values at 25 C versus
37 C (Fig. 7d–f). We then calculated values of LogBias between
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pERK1/2 (measured after 5min of agonist stimulation at 37 C)
and inhibition of cAMP production measured at time points
between 0 and 30min. After 15min at 25 C (conditions used by
Tschammer et al.18) aripiprazole was not signiﬁcantly biased
towards the inhibition of cAMP production as compared with
pERK1/2 (Fig. 7g)18. However, after 30min at 37 C (conditions
used by Szabo et al.17), aripiprazole displayed signiﬁcant bias
towards inhibition of cAMP17. Therefore, we could recapitulate
the results of the two studies, demonstrating that both
temperature and measurement time underlie the discrepancy in
their ﬁndings.
Discussion
To our knowledge, this is the ﬁrst study to demonstrate that
kinetic context, manifested by both ligand-binding kinetics and
the kinetics intrinsic to different cellular signalling processes,
can profoundly inﬂuence observations of biased agonism.
This ﬁnding has signiﬁcant implications for the design and
interpretation of studies of biased agonism across the drug
discovery ﬁeld2,13.
Biochemical, biophysical and X-ray crystallography studies
have provided evidence of ligand-dependent conformational
states of GPCRs38–42. However, for the majority of studies,
a conformation-driven mechanism of biased agonism is inferred
indirectly from pharmacological data. This assumption is
fundamental to drug-discovery efforts focused on biased
agonism2,10,27,43. Although evidence of biased agonism has
been presented for an ever-increasing number of GPCRs, these
data are often inconsistent across different studies14–18,44–45.
Such discrepancies are indicative of the effect of both
observational and system bias on the results of such studies
that confound observations of biased agonism. This hampers
drug-discovery efforts, because it challenges our ability
to correlate biased agonism with drug structure as part of
structure–activity studies or, indeed, the physiological effect
of a drug.
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Figure 5 | D2R agonists display distinct assay-dependent changes in potency over time. The response induced by various concentrations of dopamine
(a–c), ropinirole (d–f), aripiprazole (g–i) and bifeprunox (j–l) by Flp-In-CHO cells stably expressing the D2LR was determined at a range of time points
between 2 and 90min. Agonist effects were measured on the inhibition of forskolin-induced cAMP production (a,d,g,j), activation of GaoB G proteins
(b,e,h,k) and changes in CI (c,f,i,l). The data were normalized to the maximal response induced by ropinirole. The values are expressed as mean±s.e.m.
from three experiments performed in duplicate; duplicates were averaged before calculating s.e.m. The average potency (pEC50) and Emax for each drug at
each time point are displayed in Supplementary Table 7.
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In the current study, we gave particular focus to the inﬂuence
of kinetic context on biased agonism. Aripiprazole, cariprazine
and bifeprunox displayed slow dissociation kinetics that, in
functional assays, conferred an increase in potency over time
mediated by an increase in receptor occupancy29. In contrast, for
the agonists with fast dissociation kinetics, a different pattern of
decreasing potency was observed in both the cAMP and CI
readouts but not in measurements of GaoB activation. These
different signalling endpoints must thus be subject to pathway-
and drug-speciﬁc regulatory processes. It is interesting to note
that no such decrease in potency was observed for the slow
dissociating agonists. Hence, the changes in potency and efﬁcacy
over time observed for all of the ligands result from interplay
between the kinetics of ligand-binding and cell signalling
processes. These changes in potency and efﬁcacy conferred
changes in bias over time and, for the slow dissociating ligands
aripiprazole and bifeprunox, even a reversal in the direction of
bias.
Analytical methods, such as those based on the Black and Leff
operational model of agonism, have proved useful to identify
biased agonists and allow structure–activity studies to be
supplemented with a quantitative measure of bias9–11. However,
such models assume equilibrium of all reactants. In reality, this is
not the case for the majority of functional assays or in
physiological systems3,29. It has been suggested that these
methods can eliminate both system and observational bias
through the normalization of transduction coefﬁcients to a
reference agonist9,10. The data presented in this study reveal that
this approach cannot always eliminate observational bias
conferred by differential ligand binding and/or signalling
kinetics. The importance of observational bias was further
illustrated by the fact that we were able to attribute a dis-
crepancy in the observed biased action of aripiprazole between
the study of Szabo et al.17 and that of Tschammer et al.18
to differences in experimental conditions and, in particular,
temperature and measurement time. It should be noted that the
relative contributions of enthalpy and entropy to the binding of
an agonist dictate the effect of assay temperature on this binding
event46. Furthermore, cell signalling processes are also likely to be
affected by changes in temperature.
In the majority of studies, the ability of a ligand to elicit
a response is measured at a single time point selected based on a
maximal signal window obtained for a reference ligand. Such a
snapshot is likely to give an incomplete picture of drug action47.
Indeed, the idea that the observed response of a drug will vary
with time has long been acknowledged20. Although the majority
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Figure 7 | Differences in observation bias can explain discrepancies in prior studies of biased agonism. Experiments measuring ERK phosphorylation
using an Alphascreen assay were measured after 5min of agonist stimulation at 37 C, whereas experiments measuring inhibition of forskolin-stimulated
cAMP using the BRET CAMYEL biosensor were measured at various time points between 2 and 30min at either 25 or 37 C. These data were used to
determine transduction coefﬁcients (Log(t/KA)) for the different agonists at the different time points and different assays. The effect of temperature on the
DLog(t/KA) values of ropinirole (a), pardoprunox (b), S-3PPP (c), aripiprazole (d), cariprazine (e) and bifeprunox (f) was determined at various time points
using the BRET cAMP assay in reference to dopamine. *Po0.05, signiﬁcant difference between the DLog(t/KA) values determined at 25 and 37 C as
evaluated by a Student’s unpaired two-tailed t-test. The effect of temperature on biased agonism of aripiprazole (g), cariprazine (h) and bifeprunox (i) over
time between ERK1/2 phosphorylation (5min, 37 C) and the inhibition of cAMP production (x’) in reference to dopamine was evaluated. The values are
expressed as mean±s.e.m. obtained from three experiments performed in duplicate; duplicates were averaged before calculating s.e.m. *Po0.05,
signiﬁcantly different from the reference agonist dopamine at each time point determined by a Student’s unpaired two-tailed t-test.
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of signal readouts in our study maintained a robust signal for all
agonists over 90min, ERK1/2 phosphorylation was remarkably
more transient in nature for all ligands. Therefore, at the time of
maximal signal window, the level of receptor occupancy for slow
dissociating agonists such as bifeprunox will be low. Indeed, a
recent study at the serotonin 5-HT2B receptor demonstrated that
the potency of slow dissociating agonists was underestimated
when transient signalling events were measured48. Thus, agonists
with slow dissociation kinetics may display an apparent bias
towards pathways that are measured at longer time, because
receptor occupancy will be higher. We observe such a pattern for
the slow dissociating agonists when comparing their action in a
pERK1/2 assay measured at 5min and a cAMP assay measured at
longer time points.
A number of studies have attempted to relate measurements of
biased agonism to ligand structure, to build structure–activity
relationships of biased agonism15,43,49–52. The majority of
such studies are performed in heterologous systems with the
expectation that a bias phenotype (for example, bias towards a
b-arrestin pathway over a G protein-dependent pathway) will be
maintained in the (patho)physiologically relevant cell background
or tissue. Our ﬁnding that the magnitude and direction of bias
may change over time adds a further layer of complexity to the
interpretation of such studies. In this study, although drugs
(bifeprunox, cariprazine and aripiprazole) that displayed a
distinct bias proﬁle at 5min remained biased relative to
ropinirole at 90min, the direction of bias changed. In such
cases, ascribing directionality to the description of a biased ligand
(for example, bias towards G protein activation) may be an
insufﬁcient descriptor of the action of a drug, as bias determined
at an acute time point may differ considerably from the bias
observed after longer drug administration. Indeed, descriptions of
bias direction should be qualiﬁed with the conditions in which
this bias was detected including time point(s).
Our data do not exclude a mechanism by which biased
agonism is conferred by the stabilization of distinct receptor
conformations by different ligands. Such a mechanism may be
concomitant with differential binding kinetics, whereby the
duration of a ligand–receptor complex determines the different
effector and regulatory proteins that can be engaged over time.
Thus, we propose ‘kinetic bias’ as a mechanism that can modify
the apparent energy landscape of GPCRs at different time points
(Fig. 8). Indeed, an endogenous ligand may have a ‘natural’
signalling pleiotropy that changes over time as the agonist–
receptor complex engages distinct transducer proteins, that is,
G proteins or b arrestins. Other agonists acting at the same
receptor may engage signalling and regulatory pathways to
different extents in a time-dependent manner. Although
conformational selection (by both ligand and transducer) must
be the fundamental underlying mechanism by which biased
agonism is manifested, our ﬁndings suggest that ligand-binding
kinetics relative to signalling endpoints must now be routinely
considered. A number of studies have demonstrated the ability of
some receptors to maintain sustained signalling following
internalization47,53–55. Of interest, recent studies have suggested
a link between long ligand residence time and both the prolonged
internalization of the S1P1 receptor and persistent signalling from
internalized 5-HT2B receptors and calcitonin receptors48,56,57.
It is interesting to note that the three ligands that displayed slower
dissociation kinetics than dopamine have all shown antipsychotic
efﬁcacy in clinical trials, and that slow dissociation kinetics of
D2R partial agonists have been linked to reduced prolactin
release58. Although the propensity of antagonist antipsychotic
drugs to cause extrapyramidal side effects has been linked to their
dissociation rate from the D2R, future studies are required to
understand the link between the dissociation rate of D2R partial
agonists and their therapeutic efﬁcacy.
Our ﬁndings suggest that the linking of a cellular mechanism of
biased agonism to the physiological effect of a drug represents a
signiﬁcant challenge. Ideally, one could screen for biased ligands
in the physiologically relevant tissue and provide unequivocal
evidence that is the biased action of a ligand that leads to its
differential action. However, such an approach is not practical for
the screening of a large number of compounds and requires a
detailed understanding of the physiological system and, in
particular, the relationship between different signalling pathways
and physiological effect. In the vast majority of cases, such
information is incomplete or missing. Thus, the screening of
ligands at multiple signalling endpoints in a simple cell system
that allows one to study the action of drugs at a single GPCR
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target, in combination with analytical methods (such as those
based on the operational model of agonism) to quantify this
agonist action and to allow comparison across different pathways,
represents a practical compromise. These measurements can then
be used to ‘cluster’ ligands based on their effects across different
pathways. Based on our ﬁndings, we now propose that selected
ligands from each cluster be subsequently assessed in terms of
kinetic proﬁling, to identify those that may be expressing their
bias predominantly through a kinetic mechanism. Finally,
exemplar molecules can then be progressed into more complex,
physiologically relevant systems to see whether this bias proﬁle
confers differential effects in this system. Therefore, we propose
that an operational approach to quantify drug action together
with the measurement of ligand-binding kinetics may allow a
more informed clustering of compounds. This in turn will
provide an improved foundation for drug discovery of biased
agonists.
Methods
Materials. Aripiprazole and cariprazine were synthesized in-house as previously
described7,52. Bifeprunox and pardoprunox were synthesized in-house as described
in the Supplementary Methods. All compounds were shown to be 495% pure.
Ropinirole was purchased from BetaPharma (Shanghai) Co. Ltd (Wujiang, China)
and 498% pure as described by the supplier. S-3PPP and dopamine were
purchased from Sigma-Aldrich (Castle Hill, NSW, Australia) and are 498% pure
as indicated by the supplier. The G protein BRET constructs were generated by
Dr Ce´line Gale´s (Paul Sabatier University, France)59. The pcDNA3L-His-CAMYEL
was purchased from ATCC. The Rluc8-tagged D2LR and YFP–b-arrestin-2
constructs were a gift from Associate Professor Michelle Glass (University of
Auckland, New Zealand). DMEM medium (DMEM) and Flp-In-CHO cells were
purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum was purchased
from ThermoTrace (Melbourne, VIC, Australia). [3H]Spiperone, AlphaScreen
reagents and Ultima gold scintillation cocktail were purchased from PerkinElmer
(Boston, MA). The Tag-lite labelling medium (LABMED), SNAP-Lumi4-Tb and
the PPHT derivative labelled with a red ﬂuorescent probe (PPHT-red) was from
Cisbio Bioassays (Bagnols-sur-Ce`ze, France). Three hundred and eighty-four-well
Optiplates plates were purchased from PerkinElmer (Beaconsﬁeld, UK). Spiperone
and DMEM/Nutrient F-12 Ham) were obtained from Sigma Chemical Co Ltd.
(Poole, UK); all other cell culture reagents including pluronic acid, Hank’s-based
cell dissociation buffer and PBS were obtained from GIBCO (Invitrogen, Paisley,
UK). All of the other reagents were purchased from Sigma-Aldrich (Castle Hill,
NSW, Australia).
Cell lines and transfection. Flp-In-CHO cells were grown in DMEM
supplemented with 10% fetal bovine serum and maintained at 37 C in a
humidiﬁed incubator containing 5% CO2. The Flp-In-CHO cells were transfected
with the pOG44 vector encoding Flp recombinase and the pDEST vector encoding
the D2LR at a ratio of 9:1 using polyethylenimine as the transfection reagent60.
Twenty-four hours after transfection, the cells were subcultured and the medium
was supplemented with 700mgml 1 HygroGold (Invivogen) as selection agent,
to obtain cells stably expressing the D2LR.
Bioluminescence resonance energy transfer. b-Arrestin-2 recruitment.
Flp-In-CHO cells were seeded at a density of 2,000,000 cells per 10-cm dish and
were transfected the following day using polyethylenimine as the transfection
reagent. To assess b-arrestin-2 recruitment to the D2LR, the cells were transfected
with 1 mg Rluc8-tagged D2LR, 4 mg YFP–b-arrestin-2 and 2 mg GRK2. Twenty-four
hours after transfection, the cells were plated into 96-well CulturPlates
(PerkinElmer) and grown overnight. The cells were equilibrated in Hank’s
balanced salt solution at 37 C before starting the experiment. The cells were
incubated with Coelenterazine (Promega) at a ﬁnal concentration of 5 mM for
5min, followed by stimulation with the agonists for an additional 5min before
the BRET readings were captured. The signals were detected at 445–505 and
505–565 nm using a LUMIstar Omega instrument (BMG LabTech, Offenburg,
Germany). Net BRET was determined by subtraction of the vehicle control from
the agonist-induced response.
Cyclic AMP. Flp-In-CHO cells stably expressing the D2LR were seeded at a
density of 2,000,000 cells per 10-cm dish and were transfected the following day
using polyethylenimine as the transfection reagent. The cells were transfected with
3 mg CAMYEL, to allow the detection of cAMP levels within the cells. Twenty-four
hours after transfection, the cells were plated into 96-well CulturPlates
(PerkinElmer) and grown overnight. The cells were equilibrated in Hank’s
balanced salt solution at 37 C (or 25 C when indicated) before starting the
experiment. The cells were co-stimulated with the agonists and 10 mM forskolin for
the indicated timeframes when the BRET readings were captured. Coelenterazine
(Promega) was added at a ﬁnal concentration of 5 mM at least 3min before
measurement. The signals were detected at 445–505 and 505–565 nm using a
LUMIstar Omega instrument (BMG LabTech). Net BRET was determined by
subtraction of the vehicle control co-added with 10 mM forskolin.
G protein activation. Flp-In-CHO cells stably expressing the D2LR were seeded
at a density of 2,000,000 cells per 10-cm dish and were transfected the following
day using polyethylenimine as the transfection reagent. To measure the activation
of Gai1 and GaOB G proteins, the cells were transfected with either 0.3 mg
Rluc8-tagged Gai1, 1.2 mg Gb and 1.35 mg Venus-tagged Gg, or 0.14 mg
Rluc8-tagged GaOB, 1.2 mg Gb and 0.6 mg Venus-tagged Gg. Twenty-four hours
after transfection, the cells were plated into 96-well CulturPlates (PerkinElmer) and
grown overnight. The cells were equilibrated in Hank’s balanced salt solution
at 37 C before starting the experiment. The cells were stimulated with the
agonists for the indicated timeframes when the BRET readings were captured.
Coelenterazine (Promega) was added at a ﬁnal concentration of 5 mM at least 3min
before measurement. The signals were detected at 445–505 and 505–565 nm using
a PHERAstar FS instrument (BMG LabTech). Net BRET was determined by
subtraction of the vehicle control from the agonist-induced response.
xCELLigence (CI) assay. Changes in CI on ligand stimulation were measured
using the xCELLigence system (Roche Applied Science). The baseline cell index of
each well of a 96-well E-plate was measured in the presence of growth medium
before cell seeding. Cells were seeded at a density of 20,000 cells per well and grown
for 16–20 h followed by 4 h serum starvation. Cells were treated with the ligands
and the cell index values were obtained immediately after ligand stimulation every
15 s for a total time of 90min. The retrieved cell index values were then normalized
by dividing the cell index at the time of ligand addition followed by subtraction of
the vehicle control at each time point.
ERK1/2 phosphorylation assay. ERK1/2 phosphorylation was measured using
the Alphascreen SureFire ERK kit (PerkinElmer, Waltham, USA). Cells were
seeded into 96-well plates at a density of 50,000 cells per well. After 5–7 h, cells
were washed with PBS and incubated in serum-free DMEM overnight before
assaying. Dose–response experiments were performed for each ligand at 37 C in
the presence of 0.1% ascorbic acid. Stimulation of the cells was terminated after
5min of agonist stimulation by removing the media and the addition of 100 ml of
SureFire lysis buffer to each well. The plate was shaken for 5min at room
temperature (RT) before transferring 5 ml of the lysates to a white 384-well
Proxiplate (PerkinElmer, Waltham, USA). Next, 8 ml of a 240:1,440:7:7 mixture
of Sureﬁre activation buffer:Sureﬁre reaction buffer:Alphascreen acceptor
beads:Alphascreen donor beads was added to the samples and incubated in
the dark at 37 C for 1.5 h. Plates were read using a Fusion-TM plate reader
(PerkinElmer, Waltham, USA).
cAMP Alphascreen assay. Flp-In-CHO cells stably expressing the D2LR were
grown overnight in 96-well plates at a density of 50,000 cells per well. After
pre-incubating the cells for 45min with stimulation buffer (Hank’s buffered salt
solution: 0.14M NaCl, 5.4mM KCl, 0.8 mM MgSO4, 1.3mM CaCl2, 0.2mM
Na2HPO4, 0.44mM KH2PO4, 5.6mM D-glucose, 1mgml 1 BSA, 0.5mM
3-isobutyl-1-methylxanthine and 5mM HEPES pH 7.4), the cells were stimulated
simultaneously with drug and 300 nM forskolin for 30min at 37 C. Stimulation of
cells was terminated by the removal of the stimulation buffer and the addition of
50 ml ice-cold 100% ethanol. The plates containing the cell lysates were then
incubated at 37 C without lid, to allow complete evaporation of the ethanol. After
all the ethanol was evaporated, 50 ml of detection buffer (1mgml 1 BSA, 0.3%
Tween-20 and 5mM HEPES pH 7.4) was added to each well. The plate was shaken
for 5min, to ensure complete and even suspension of the cell material. Five
microlitres of the sample was then transferred into a white 384-well Optiplate
(PerkinElmer, Waltham, USA). Anti-cAMP acceptor beads (0.2 units per ml)
diluted in stimulation buffer were added to all samples and incubated in the dark
at RT for 30min before addition of 15 ml of the donor beads/biotinylated cAMP
(0.07 units per ml) mixture made up in detection buffer. Following a 1-h incubation
at RT, plates were read using a Fusion-TM plate reader (PerkinElmer,
Waltham, USA).
Membrane preparation. Flp-In-CHO cells stably expressing the dopamine D2LR
were grown to 90% conﬂuency in 175 cm2 cell culture ﬂasks. The cells were
harvested in PBS containing 2mM EDTA and centrifuged at 300 g for 3min.
The resulting pellet was resuspended in ice-cold assay buffer (20mM HEPES,
100mM NaCl, 6mM MgCl2, 1mM EGTA and 1mM EDTA pH 7.4) and the
centrifugation step was repeated. The intact cell pellet was then resuspended in
assay buffer and homogenized using a Polytron homogenizer. After centrifugation
(1,000 g, 10min), the pellet was discarded and the supernatant was recentrifuged at
30,000 g for 1 h at 4 C using a Sorvall Evolution RC ultracentrifuge (Thermo
Scientiﬁc). The resulting pellet was resuspended in assay buffer and stored in 250 ml
aliquots at  80 C. Membrane protein concentration was determined using the
method of Bradford.
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[3H]Spiperone-binding assays. All radioligand binding experiments were
conducted at 37 C in a 1-ml reaction volume in assay buffer (20mM HEPES,
100mM NaCl, 6mM MgCl2, 1mM EGTA and 1mM EDTA pH 7.4) containing
100mM GppNHp and 0.1% ascorbic acid. In all cases, nonspeciﬁc binding was
determined in the presence of 10 mM haloperidol. After the indicated incubation
period, bound and free [3H]spiperone were separated by fast-ﬂow ﬁltration
through GF/B ﬁlters using a brandel harvester followed by three washes with
ice-cold 0.9% NaCl. Filter-bound radioactivity was measured by scintillation
spectrometry after the addition of 3.5ml of Ultima Gold (PerkinElmer) using
a Tri-Carb 2900TR liquid scintillation counter (PerkinElmer).
The dissociation rate of [3H]spiperone was determined by allowing 0.2 nM
[3H]spiperone to reach equilibrium with Flp-In-CHO-D2L membranes (10 mg) in a
ﬁnal volume of 1ml after which re-association of [3H]spiperone was prevented by
the addition of haloperidol. Bound [3H]spiperone was measured at multiple time
points after the addition of haloperidol. The koff determined for [3H]spiperone was
0.026min 1.
Association binding experiments were conducted to determine the kobs of
[3H]spiperone. Association was initiated by the addition of 0.2 nM [3H]spiperone
to Flp-In-CHO-D2LR membranes (10 mg) and terminated by ﬁltration. The kon of
[3H]spiperone was derived from the kobs using the koff value predetermined in
dissociation binding experiments. The kon determined for [3H]spiperone was
9.51 108M 1min 1.
The kinetic parameters of unlabelled agonists were determined using the
equations described by Motulsky and Mahan31. Both [3H]spiperone and unlabelled
agonist were simultaneously added to Flp-In-CHO-D2LR membranes (10mg). The
amount of [3H]spiperone bound to the receptor was assessed at multiple time
points. To ensure that the rate parameters calculated for the unlabelled agonists
were independent of ligand concentration, the experiment was performed in the
presence of two or three different concentrations of unlabelled agonist.
To obtain afﬁnity estimates of unlabelled agonists, [3H]spiperone competition
experiments were performed at equilibrium. The ability of increasing
concentrations of the agonists to compete with 0.1 nM [3H]spiperone for binding
to the D2LR was tested. The membranes (Flp-In-CHO-D2LR, 5 mg) were incubated
with the drugs for 3 h at 37 C. The Ki values of the unlabelled agonists were
determined using the KD of [3H]spiperone (0.028 nM), which was obtained from
kinetic experiments.
Cell culture and terbium labelling of SNAP-tagged D2L cells. Chinese hamster
ovary cells transfected with the complementary DNA encoding a SNAP-tagged
human dopamine D2L (SNAP-CHO-D2L) receptor were maintained in DMEM/
Nutrient F-12 Ham, 2mM glutamine supplemented 10% FCS. To terbium label the
SNAP-CHO-D2L cells, cell culture medium was removed from the T175 cm2 ﬂasks
containing conﬂuent adherent SNAP-CHO-D2L cells. Twelve millilitres of Tag-lite
labelling medium containing 100 nM of SNAP-Lumi4-Tb was added to the ﬂask
and incubated for 1 h at 37 C under 5% CO2. Cells were then washed 2 in 15ml
PBS (GIBCO, Invitrogen, Paisley, UK) to remove the excess of SNAP-Lumi4-Tb
and detached using 5ml of enzyme-free Hank’s-based cell dissociation buffer
(GIBCO, Invitrogen, Paisley, UK) and collected in a vial containing 5ml of
DMEM/Nutrient F-12 Ham, 2mM glutamine supplemented 10% FCS. Cells were
pelleted by centrifugation (5min at 1,500 r.p.m.) and the pellets were frozen to
 80 C before preparation of membranes.
Membrane preparation of terbium-labelled cells. All subsequent steps described
were conducted at 4 C, to avoid receptor degradation. Twenty millilitres of wash
buffer (10mM HEPES and 10mM EDTA pH 7.4) was added to the pellet of
terbium-labelled cells (equivalent to 1 t175 cm2). This was homogenized using an
electrical homogenizer Ultra-Turrax (Ika-Werk GmbH & Co. KG, Staufen,
Germany) (position 6, 5 1 s bursts) and subsequently centrifuged at 48,000 g at
4 C (Beckman Avanti J-251 Ultracentrifuge; Beckman Coulter, Fullerton, CA)
for 30min. The supernatant was discarded and the pellet was homogenized and
centrifuged as described above in wash buffer. The ﬁnal pellet was suspended
in ice-cold 10mM HEPES and 0.1mM EDTA pH 7.4, at a concentration of
5–10mgm 1. Protein concentration was determined by the bicinchoninic acid
assay using BSA as a standard and aliquots maintained at  80 C until required.
Before their use, the frozen membranes were thawed and the membranes
suspended in the assay buffer at a membrane concentration of 0.1mgm 1.
Fluorescent ligand-binding assays. All ﬂuorescent binding experiments using
PPHT-red were conducted at 37 C in 384-well Optiplates plates, in assay binding
buffer, 20mM HEPES, 100mM NaCl, 6mM MgCl2, 1mM EGTA, 1mM EDTA
and pluronic acid 0.02% pH 7.4, containing 100 mM GppNHp and 0.1% ascorbic
acid. GppNHp was included to remove the G protein-coupled population of
receptors that can result in two binding sites in membrane preparations, because
the Motulsky–Mahan model is only appropriate for ligands competing at a single
site. In all cases, nonspeciﬁc binding was determined in the presence of 1 mM
spiperone. Both ﬂuorescent ligands and unlabelled compounds were diluted in the
binding assay buffer.
Time resolved ﬂuorescence resonance energy transfer signals were acquired in a
PHERAstarFS plate reader (BMG Labtech) equipped with a Homogeneous Time
Resolved Fluorescence module capable of excitation at 337 nm and emission at 620
and 665 nm. Kinetics acquisitions at intervals of 20 s were recorded using the
standard settings of the reader for HTRF measurements. The Terbium donor was
excited with three laser ﬂashes at a wavelength of 337 nm and time-resolved
recording of the acceptor and donor emission took place at 620 and 665 nm,
respectively, using the default settings of the instrument. HTRF ratios were
obtained by dividing the acceptor signal (665 nm) by the donor signal (620 nm)
and multiplying this value by 10,000. Speciﬁc binding was determined by
subtracting the nonspeciﬁc HTRF ratio from the total HTRF ratio.
Determination of PPHT-red binding kinetics. To accurately determine
association rate (kon) and dissociation rate (koff) values, the observed rate of
association (kob) was calculated using at least four different concentrations of
PPHT-red. The appropriate concentration of PPHT-red was incubated in a
384-well Optiplate with human SNAP-D2LR-CHO cell membranes (2 mg per well)
in assay binding buffer at 37 C (ﬁnal assay volume, 40ml). The degree of
PPHT-red bound to the receptor was assessed at multiple time points by HTRF
detection, to allow construction of association kinetic curves. The resulting data
were globally ﬁtted to the association kinetic model (equation (8)) to derive a single
best-ﬁt estimate for kon and koff as described under ‘Data analysis’.
Competition binding kinetics. On the same 384-well Optiplate plate, the kinetic
parameters of unlabelled ligand were assessed using a competition kinetic binding
assay. This approach involves the simultaneous addition of both ﬂuorescent
ligand and competitor to receptor preparation so that at t¼ 0 all receptors are
unoccupied. PPHT-red (12.5 nM; a concentration that avoids ligand depletion in
this assay volume) was added simultaneously with the unlabelled compound
(at t¼ 0) to CHO cell membranes containing the human D2L (2 mg per well) in
40 ml of assay buffer. The degree of PPHT-red bound to the receptor was assessed at
multiple time points by HTRF detection. Nonspeciﬁc binding was determined as
the amount of HTRF signal detected in the presence of spiperone (1 mM) and was
subtracted from each time point. Each time point was conducted on the same
384-well plate incubated at 37 C with shaking (100 r.p.m.) after every cycle.
Multiple concentrations of unlabelled competitor were tested, for determination
of rate parameters based up on the afﬁnities determined from the [3H]spiperone
competition binding assays described above. Data were globally ﬁtted using
equation (7), to simultaneously calculate kon and koff. Different ligand
concentration ranges were chosen, as compounds with a long residence time
equilibrate more slowly; thus, a higher relative concentration is required to ensure
the experiments reach equilibrium within a reasonable time frame, while still
maintaining a good signal-to-noise. Ki values of the compounds were determined
from competitive binding experiments according to the Cheng and Prusoff
equation61 as described under ‘Data analysis’.
Data analysis. The results were analysed using Prism 6.0 (GraphPad Software
Inc., San Diego, CA).
Dose–response curves were ﬁtted using the following three parameter equation
Response ¼ Bottomþ TopBottom
1þ 10ðlog EC50  log ½AÞ ð1Þ
where Top and Bottom represent the maximal and minimal asymptote of the
dose–response curve, [A] is the molar concentration of agonist and EC50 is the
molar concentration of agonist required to give a response half way between
bottom and top. Dose–response data were ﬁtted to the following form of the
operational model of agonism12 to allow the quantiﬁcation of biased agonism
Y ¼ Basalþ ðEm  basalÞð
t
KA
Þn½An
A½ nð tKAÞ
n þð1þ A½ KAÞ
n ð2Þ
where Em is the maximal possible response of the system, Basal is the basal level of
response, KA represents the equilibrium dissociation constant of the agonist (A)
and t is an index of the signalling efﬁcacy of the agonist that is deﬁned as RT/KE,
where RT is the total number of receptors and KE is the coupling efﬁciency of each
agonist-occupied receptor, and n is the slope of the transducer function that links
occupancy to response. The analysis assumes that the transduction machinery used
for a given cellular pathway are the same for all agonists, such that the Em and
transducer slope (n) are shared between agonists. Data for all compounds for each
pathway were ﬁt globally, to determine values of KA and t. Biased agonism was
quantiﬁed as previously described62. In short, to exclude the impact of cell-
dependent and assay-dependent effects on the observed agonism at each pathway,
the log(t/KA) value of a reference agonist, in this case ropinirole or dopamine, is
subtracted from the log(t/KA) value of the agonists of interest to yield Dlog(t/KA).
The relative bias can then be calculated for each agonist at the two different
signalling pathways by subtracting the Dlog(t/KA) of one pathway from the other
to give a DDlog(t/KA) value, which is a measure of bias. A lack of biased agonism
will result in values of DDlog(t/KA) not signiﬁcantly different from 0 between
pathways. All afﬁnity (pKi or pKA), potency (pEC50) and transduction ratio (log(t/
KA)) parameters were estimated as logarithms. When fold changes in bias are
described, this was calculated by converting values of DDlog(t/KA) to the
corresponding antilog value. However, we have previously demonstrated that such
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a distribution of these parameters does not conform to a normal (Gaussian)
distribution, whereas the logarithm of the measure is approximately Gaussian63.
Thus, as the application of t-tests and analyses of variance assume Gaussian
distribution, estimating the parameters as logarithms allows valid statistical
comparison. All results are expressed as the mean±s.e.m. As such, we performed a
Brown–Forsythe test (Graphpad prism 6) to assure ourselves of equal variance
when such parameters are compared.
The concentration of agonist that inhibited half of the [3H]spiperone binding
(IC50) was determined using the following equation
Y ¼ BottomþðTopBottomÞ
1þ 10ðX log IC50ÞnH ð3Þ
where Y denotes the percentage-speciﬁc binding, Top and Bottom denote the
maximal and minimal asymptotes, respectively, IC50 denotes the X-value when the
response is midway between Bottom and Top, and nH denotes the Hill slope factor.
IC50 values obtained from the inhibition curves were converted to Ki values using
the Cheng and Prusoff equation61.
The dissociation data were ﬁtted to a one-phase exponential decay function and
the t1/2 value obtained was transformed into a koff rate using the following
equation:
koff ¼ ln 2ð Þt1=2
ð4Þ
[3H]spiperone association data were ﬁtted to a single-phase exponential association
function to calculate an observed rate constant kob. The association rate constant,
kon, was calculated as described originally by Hill63:
kon ¼ ðkob  koff Þ½Radioligand ð5Þ
where the koff value used was predetermined from dissociation experiments. These
parameters can then be used to calculate the radioligand equilibrium dissociation
constant, KD:
KD ¼ koffkon ð6Þ
Association and dissociation rates for unlabelled agonists were calculated by ﬁtting
the equations described by Motulsky and Mahan31:
KA ¼ k1 L½  þ k2
KB ¼ k3 I½  þ k4
S ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðKA KBÞ2 þ 4k1k3LI10 18
q
KF ¼ 0:5ðKA þKB þ SÞ
KS ¼ 0:5ðKA þKB  SÞ
Q ¼ Bmaxk1L
KF KS
Y ¼ Q k4 KF KSð Þ
KFKS þ
k4 KF
KF
eKFX  k4 KS
KS
eKSX
 
ð7Þ
where X is time (min), Y is speciﬁc binding, k1 is kon [3H]spiperone (M 1min 1),
k2 is koff [3H]spiperone (min 1), L is the concentration of [3H]spiperone used (M)
and I is the concentration of unlabelled agonist (M). Fixing the above parameters
allowed the calculation of the following parameters: the maximum number of
receptor sites Bmax, the association rate of the unlabelled agonist k3 (M 1min 1)
and the dissociation rate of the unlabelled agonist k4 (min 1).
PPHT-red association data were globally ﬁtted to equation (8), where L is the
concentration of ligand in nM using GraphPad Prism 6.0, to determine a best-ﬁt
estimate for kon and koff.
kob ¼ L½ kon þ koff ð8Þ
Association and dissociation rates for unlabelled agonists were calculated by ﬁtting
to equation (7), described above for [3H]-spiperone binding, except k1 is kon
PPHT-red (M 1min 1), k2 is koff PPHT-red (min 1), L is the concentration of
PPHT-red used (M).
The simulation displayed in Fig. 3 was performed using the equation
Y ¼ Ymax  1 e kob :t
  ð9Þ
where Ymax reﬂects maximum binding of a concentration of ligand and kob is
determined by equation (8).
Principal component analysis. PCA is a dimensionality reduction method that
uses transformations to project a high-dimensional set of data into a lower
dimensional set of variables called principal components. The principal
components extract the important information from the data, revealing its internal
structure in a way that best explains its variance28. The PCA was applied using
singular value decomposition as implemented in the package scikit-learn64.
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